which glp 1 agonist is approved for weight loss Indications GLP-1/GIP RA Summary Sheet and Beyond! GLP-1 Agonists For Obesity In

That fiscal backdrop helps explain why most public plans have so far limited GLP1 coverage to diabetes, even as evidence for weightloss and cardiometabolic benefits in people with obesity has grown

If a patient stops the medication, diabetes will relapse (if it was controlled, not cured) and weight will likely be regained, as evidenced by trials where cessation led to weight regain trends

and a discussion with the patient regarding the potential need for rapid sequence induction (RSI) to minimize aspiration risk, versus postponement of the procedure

doi: 10.1517/14740338.2013.793671

Yamanouchi D

Exenatide immediate-release (Byetta): Initiation involves a 5 mcg dose administered subcutaneously twice daily, which can be increased to 10 mcg twice daily after a month if required